Circulating cell-free and EpsteinBarr virus DNA in pediatric B-non-Hodgkin lymphomas

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 1020-1027

  MacHado, Alex S C ^a   Da Silva Robaina, Marcela C ^a   Magalhães De Rezende, Lidia M ^a   Apa, Alexandre G ^a   Amodo, Nvea D ^b   Bacchi, Carlos E ^c   Klumb, Claudete E ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UFRJ ^*  (Brazil)

Author keywords

B non Hodgkin lymphoma; Cell free DNA; Circulating DNA; EpsteinBarr virus; Quantitative PCR; Viral load

Indexed keywords

CIRCULAR DNA; VIRUS DNA; ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD; BLOOD; EPSTEIN BARR VIRUS INFECTION; GENETICS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; OUTCOME ASSESSMENT; PHYSIOLOGIC MONITORING; POLYMERASE CHAIN REACTION; PROCEDURES; PROGNOSIS; VIROLOGY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); POLYMERASE CHAIN REACTION; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 77953522826     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003746331     Document Type: Article

References (38)

1. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-323.
2. Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001;47:137-139.
3. Wataganara T, Bianchi DW. Fetal cell-free nucleic acids in the maternal circulation: new clinical applications. Ann NY Acad Sci 2004;1022:90-99.
4. Vasavda N, Ulug P, Kondaveeti S, et al. Circulating DNA: a potential marker of sickle cell crisis. Br J Haematol 2007;139: 331-336.
5. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164.
6. Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cellfree tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15: 1032-1038.
7. Bremnes RM, Sirera R, Camps C. Circulating-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12.
8. Rogers A, Joe Y, Manshouri T, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 2004;103:2799-2801.
9. Schwarz AK, Stanulla M, Cario G, et al. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 2009;88:897-905.
10. Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 2009;20:1408-1413.
11. Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. Mol Diagn 2001;6:279-289.
12. Ryan JL, Fan H, Swinnen LJ, et al. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 2004;13: 61-68.
13. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-2470.
14. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60: 6878-6881.
15. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000;111:239-246.
16. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBVpositive lymphomas in immunocompetent patients. Blood 2004;104:243-249.
17. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein- Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006;12:460-464.
18. Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol 2004;26:462-468.
19. Swerdlow SH, Campo E, Harris NL, et al.WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
20. Queiroga EM, Gualco G, Weiss LM, et al. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol 2008;130:946-956.
21. Klumb CE, Hassan R, De Oliveira DE, et al. Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil. Int J Cancer 2004;108:66-70.
22. Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987;61:1743-1746.
23. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Onco. 1989;7:186-193.
24. Machado AS, Apa AG, Magalhães de Rezende LM, et al. Plasma Epstein-Barr viral load predicting response after chemotherapy for post-transplant lymphoproliferative disease. Clin Exp Med 2008;8:129-132.
25. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkittlike lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 2003;120:660-670. (Pubitemid 36255868)
26. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-2743.
27. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007;109:2773-2780.
28. Lovisa F, Mussolin L, Corral L, et al. IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Lab Invest 2009;89:1182-1186.
29. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003;103:149-152.
30. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-271.
31. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-2470.
32. Chan KC, Lo YM. Clinical applications of plasma Epstein- Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA. Methods Mol Biol 2006;336:111-121.
33. Leung SF, Tam JS, Chan AT, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein- Barr viral capsid antigen IgA antibody. Clin Chem 2004;50:339-345.
34. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein- Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539-546.
35. Kim HS, Kim KH, Kim KH, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009;50:757-763.
36. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002;48:421-427.
37. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann NY Acad Sci 2000;906:161-168.
38. Van der Auwera I, Elst HJ, Van Laere SJ, et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009;100:1277-1286